Clinical trials: Diabetes, Type II
Diabetes Mellitus, Type 2, Medication Adherence
The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes
A 4 week prospective, randomized controlled study was carried out to assess the impact of a care delivery intervention which focused on blood glucose (BG) management among adults with type 2 diabetes presenting to the Emergency…
- Conditions
- Diabetes Mellitus, Type 2, Medication Adherence, HYPERGLYCEMIA
- Trial name
- STEP-DM (NCT02269098)
- Testing
- Diabetes medication management
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Medstar Health Research Institute
Type 2 Diabetes
Use of Continuous Glucose Monitors in Publicly-Insured Youth With Type 2 Diabetes - A Pilot and Feasibility Study
The purpose of this pilot feasibility study is to provide continued CGM access to youth with type 2 diabetes and collect descriptive data about feasibility of use of CGM in youth with type 2 diabetes ages 4 years and older.
- Trial name
- NCT05074667
- Testing
- Continuous Glucose Monitor, Patient Reported Outcome Questionnaires
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Type 2 Diabetes Mellitus
A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects
Previous studies have suggested that a once-weekly formulation of exenatide may provide sustained glycemic control. These previous studies of exenatide once weekly have been conducted in non-Asian populations, so this study has…
- Trial name
- NCT00917267
- Testing
- exenatide once weekly, exenatide twice daily
- Where
- 42 sites in China, India and 3 more
- Volunteers
- 691 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 Diabetes Mellitus treated with insulin.
- Trial name
- PIONEER 8 (NCT03021187)
- Testing
- semaglutide
- Where
- 118 sites in United States, Canada and 8 more
- Volunteers
- 731 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study In Patients With Type 2 Diabetes Mellitus
This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations.
- Trial name
- NCT00256867
- Testing
- GSK523338
- Where
- 85 sites in United States, Australia and 4 more
- Volunteers
- 369 people
- Sponsor
- GlaxoSmithKline
Type2 Diabetes, Diabetes Mellitus
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D
- Trial name
- SURPASS-PEDS (NCT05260021)
- Testing
- Tirzepatide Dose 1, Tirzepatide Dose 2
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 99 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
The aim of this study is to investigate the impact of the combination therapy of linagliptin and metformin at submaximal doses in reduction of Glycosylated haemoglobin (HbA1c) and metformin pre-specified gastro-intestinal (GI)…
- Trial name
- NCT01438814
- Testing
- metformin, linagliptin
- Where
- 90 sites in Bangladesh, Belgium and 12 more
- Volunteers
- 689 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
The objective of this study is to assess the effect of the different degrees of renal impairment on the pharmacokinetics, pharmacodynamics and safety of BI10773 following oral administration of high dose BI10773 as a single dose…
- Trial name
- NCT01581658
- Testing
- BI10773
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus (DM)
Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM
Purpose: To compare efficacy and safety of traditional sliding scale insulin (SSI) versus modified 70/30 insulin versus modified basal plus supplemental scale /bolus insulin regimens for glycemic control in hospitalized diabetic…
- Trial name
- NCT01855243
- Testing
- regular insulin, 70/30 insulin, Glargine
- Where
- Egypt
- Volunteers
- 63 people
- Sponsor
- Cairo University
Diabetes Mellitus, Type 2
Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
Primary Objective: To assess patient preference for Lantus SoloSTAR pen versus Lantus vial and syringe at the end of Crossover Phase (Week 4) in patients with type 2 diabetes mellitus (T2DM) Secondary Objectives: To compare…
- Trial name
- Pen Preference (NCT01226043)
- Testing
- Insulin Glargine
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- Sanofi
Type 2 Diabetes
Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes
Diet beverages sweetened with artificial sweeteners occupy a unique category in the food environment as they are a source of intensely sweet taste with no calories.
- Trial name
- SODAS (NCT03944616)
- Testing
- Diet Beverage, Water
- Where
- 2 sites in United States
- Volunteers
- 181 people
- Sponsor
- University of California, Irvine
Type 2 Diabetes
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple…
- Trial name
- TRANSITION-T2D (NCT04538352)
- Testing
- Semaglutide, Insulin Degludec, Insulin aspart
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Cleveland Clinic
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- AMPLITUDE-L (NCT03713684)
- Testing
- Efpeglenatide SAR439977, Background therapy
- Where
- 47 sites in United States, China and 1 more
- Volunteers
- 370 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers
Proton pump inhibitors (PPIs) are treatment of choice for different gastrointestinal disorders common in type 2 diabetes. Sulfonylureas (SUs) are anti-diabetes agents particularly widely used in developing countries.
- Trial name
- INTERGLIKOM (NCT04198948)
- Testing
- Omeprazole, Gliclazide
- Where
- Bosnia and Herzegovina
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Sarajevo
Diabetes Mellitus, Type 2
A Study of LY2922083 in Healthy Participants and Participants With Diabetes
The aim of this trial is to evaluate the safety of the study drug in healthy participants and participants with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to…
- Trial name
- NCT01748552
- Testing
- LY2922083
- Where
- Singapore
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients…
- Trial name
- VADT (NCT00032487)
- Testing
- Insulin, Glimepiride, Rosiglitazone
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 1,791 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Treated With Insulin
A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
- Trial name
- 2IQP (NCT05785832)
- Testing
- t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
- Where
- 21 sites in United States, Canada
- Volunteers
- 319 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes
This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs)…
- Trial name
- SWITCH 2 (NCT02030600)
- Testing
- insulin degludec, insulin glargine
- Where
- 166 sites in United States, Puerto Rico
- Volunteers
- 721 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake
The purpose of this study is to determine if, once a favorable dose of TI Inhalation Powder is established for either a type 1 or 2 patient, based on a average diabetic meal, the patient's favorable dose can be used safely…
- Trial name
- NCT00747006
- Testing
- TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mannkind Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.